The Business Research Company’s global market reports are now updated with the latest market sizing information for the year 2023 and forecasted to 2032

The Business Research Company’s eylea market report forecasts the eylea market size to grow to $9.33 Billion by 2027, with a CAGR (compound annual growth rate) of more than 4%.

Learn More On The Eylea Market Report 2023 – https://www.thebusinessresearchcompany.com/report/eylea-global-market-report

Eylea Market Size Forecast
The global eylea market is expected to grow from $7.42 billion in 2022 to $7.79 billion in 2023 at a compound annual growth rate (CAGR) of 5.0%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The global eylea market size is expected to grow to $9.33 billion in 2027 at a CAGR of 4.6%.

North America held the largest eylea market share, and Asia-Pacific was the fastest-growing region in 2022.

Key Eylea Market Driver ­– Increase In The Prevalence Of Ocular Diseases
According to the Centres for Disease Control and Prevention (CDC), a US-based national public health body, the number of patients with AMD in the US climbed to 2.95 million in 2020. AMD affects around 1.8 million Americans over the age of 40, with an additional 7.3 million at risk of getting the disease. As a result, the rising prevalence of eye illnesses is propelling the Eylea market.

Request for A Sample Of The Global Eylea Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=9155&type=smp

Key Eylea Market Trend – Adopting Research And Developments
The key industrial participants in eylea place a high premium on developing cutting-edge technical solutions. For example, in February 2020, Regeneron Pharmaceuticals, Inc., a worldwide biotechnology firm based in the United States that develops medicine for critical disorders, announced positive two-year findings from the Phase III PANORAMA testing EYLEA 2 mg injection. The trials demonstrated a 75% reduction in vision-threatening incidents. Furthermore, the company announced phase III trials of high-dose (8 mg) aflibercept in DME in 2020, which will evaluate dosing intervals of 12 weeks or longer.

Eylea Market Segment
1) By Product: Prefilled Syringe Package, Vial Package
2) By Disorder: Wet Age-Related Macular Degeneration (AMD), Diabetic Retinopathy, Other Disorders
3) By Application: Hospitals, Retail Pharmacy, Other Applications

Eylea Market Major Players and Strategies
Major players in the eylea market are Regeneron Pharmaceuticals Inc., Bayer AG, Santen Pharmaceutical Co Ltd., Momenta Pharmaceuticals Inc., Novartis AG, Mylan N V, Vertex Pharmaceuticals, Alvotech SA, Sanofi SA, F. Hoffmann-La Roche AG, PV Pharma, Alteogen Inc., Viatris Inc., Biocon Biologics Limited, and Nexus Lifecare.

Alvotech, a Luxembourg-based major worldwide biotechnology business specialising in biosimilars, announced an undisclosed partnership with Teva Pharmaceutical Industries Ltd in August 2020. The businesses are likely to work together to enhance their biosimilar market in the United States. Furthermore, this collaboration expedites and expands the patient experience as well as state-of-the-art biologics manufacturing. Teva Pharmaceutical Industries Ltd. is a significant pharmaceutical business established in Israel that specialises in generic medications.

The Eylea Global Market Report 2023 covers regional data on eylea market size, eylea market trends and drivers, opportunities, strategies, and eylea market competitor analysis. The countries covered in the eylea market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA, and the major seven regions are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa.

Eylea is an injectable medicine that helps reduce vision loss and other disorders by preventing fluid leakage and growth from faulty blood vessels in the rear of the eye. It is employed in the treatment of age-related macular degeneration (AMD).

View More Reports Related To The Eylea Market –
Vascular Endothelial Growth Factor (VEGF) Inhibitor Global Market Report 2023
Electronic Design Automation Software Global Market Report 2023
Product Engineering Services Global Market Report 2023

Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at [email protected]

Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Found this article helpful? Share it on: